Search results
Showing results for
Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.
Christiane Dolecek
MD PHD FRCP Christiane Dolecek - Professor of Global Health
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
Phaik Yeong Cheah
Phaik Yeong Cheah - Professor of Global Health
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Bridget Wills
Bridget Wills - Professor of Tropical Medicine
Paul Newton
Paul Newton - Professor of Tropical Medicine
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Direk Limmathurotsakul
Direk Limmathurotsakul - Professor of Infectious Disease Epidemiology
Richard Hoglund
Richard Hoglund - Head of Pharmacometrics
Mehul Dhorda
Mehul Dhorda - DeTACT-Africa Coordinator / Head of Specimen Management Laboratory
Raph Hamers
MD PhD Raph Hamers - Associate Professor in Infectious Diseases
Stuart Blacksell
BAppSc MPH PhD RBP(ABSA) FASM FFSc(RCPA) TechIOSH Stuart Blacksell - Professor of Tropical Microbiology